Evidence map›Paper›PMID 24494140›Full record

ArticleAddiction & health

Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents.

Hassan Ziaaddini, Mansooreh Nasirian, Nouzar Nakhaee

Open access · greenAbstract read
In one paragraph

Article in Addiction & health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pharmacological therapies for management of opium withdrawal.The Cochrane database of systematic reviews · 2018
    Pooled it
  2. Buprenorphine for managing opioid withdrawal.The Cochrane database of systematic reviews · 2017
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Trial of tramadol plus gabapentin for opioid detoxification.Iranian Red Crescent medical journal · 2015
    Article
  9. Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2014
    Review
  10. Outcome evaluation of therapeutic community model in iran.International journal of health policy and management · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hassan ZiaaddiniAssociate Professor, Neuroscience Research Center AND School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Mansooreh NasirianPsychiatrist, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Nouzar NakhaeeProfessor, Kerman Neuroscience Research Center, Department of Social Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Kerman University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSince the number of drug users is increasing, applying a method of detoxification with fewer side effects during withdrawal from opioids and greater reliability seems to be necessary. In addition, without maintenance treatment, there will be limited success of treatment. This study aimed to compare success rates of detoxification with sublingual buprenorphine and clonidine and to evaluate addiction relapse in patients using naltrexone in a six-month follow-up.

methodsThis double-blind trial was carried out on opioid dependent patients in a psychiatric hospital in Kerman (Iran) during 2007-09. The subjects were randomly selected from individuals who had referred for detoxification. They were allocated to two groups to receive either clonidine (n = 21) or buprenorphine (n = 14). The success rates of the two methods were assessed at the end of the course and patients were discharged while prescribed with 25 mg daily use of naltrexone. They were followed up for six months and the continuous use of naltrexone and relapse of substance abuse were evaluated.

findingsA total number of 35 patients entered the study. Success of detoxification with naltrexone was confirmed in all cases. One person (8.4%) in the clonidine group and no patient in the buprenorphine group had a clinical opiate withdrawal scale (COWS) score of more than 12 (P > 0.05). The mean levels of objective signs and subjective symptoms of withdrawal and the desire for drug abuse had significant reductions during detoxification period in both groups (P < 0.001). However, the difference in these variables between the two groups was not statistically significant (P > 0.05). Naltrexone was used for an average of one month in 43% and 64% of subjects in the clonidine and buprenorphine groups, respectively. In addition, 62% of patients in the clonidine group and 92.8% of subjects in the buprenorphine group received maintenance treatment. Nevertheless, the mean number of days staying in treatment was not significantly difference between the two groups (P > 0.05).

conclusionBuprenorphine is as effective as clonidine in controlling withdrawal symptoms. A greater percentage of patients detoxified by buprenorphine received maintenance treatment, but there was not a significant difference in relapse rates between the two methods.

Indexed as

Addiction relapseBuprenorphineClonidineNaltrexoneOpioid detoxification

Identifiers

PMID24494140
PMCPMC3905537
OpenAlexW2203917927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.